Skip to content

Canada vaping market access: federal requirements and provincial checkpoints

Also in Market Access

Summary. A B2B guide to Canadian vaping requirements covering product classification, nicotine and packaging rules, reporting, youth access, promotion and excise duties. Selected provincial examples show why the product, operator’s activity and destination must be assessed together—not treated as national clearance.

Scope and verification date

Research accessed: 19 November 2026 (Asia/Shanghai). This is a B2B introductory guide for manufacturers, importers, distributors and retailers of non-cannabis vaping products, including businesses considering distance sales. It is not a province-by-province operating manual or clearance for a particular product, premises, shipment or advertisement.

The federal Justice Laws consolidations retrieved for the core rules state that they are current to 29 October 2026. Accessing them on 19 November does not change that legislative currency date. Supplementary checks included the Canada Gazette Part II indexes of 4 and 18 November; neither index listed a vaping-specific instrument. That is a bounded update check, not a certification that every legislative, judicial or local development has been captured. S01 S39 S41 S42

For regional navigation, see VapeVisa’s North America market section. It is a regional page anchor, not a Canadian legal register or an existing Canadian article.

Competent authorities and regulatory framework

Consumer products and health products follow different routes

Health Canada administers the Tobacco and Vaping Products Act (TVPA). Non-therapeutic consumer vaping products are also subject to the Canada Consumer Product Safety Act (CCPSA) and applicable product regulations. The CCPSA framework includes the prohibition on manufacturing, importing, advertising or selling a consumer product that is a danger to human health or safety; meeting a label specification does not replace the wider safety assessment. S01 S12 S44

Under TVPA section 2, a vaping product can be an aerosol-producing device intended to be brought to the mouth, a part, or a substance intended for use with the device, whether or not it contains nicotine. The definition excludes cannabis and cannabis accessories, tobacco products and their accessories, and regulatory exclusions. A nicotine-free liquid or empty device is therefore not automatically outside the TVPA. S01

Health Canada’s notice distinguishes ordinary vaping products without health claims from vaping health products. Products making health claims—including smoking-cessation claims—require assessment under the Food and Drugs Act and the relevant authorization route before commercial importation, advertising or sale. The notice also identifies establishment or site-licensing requirements for regulated health-product activities. S20

Do not assume that health-product authorization removes every TVPA requirement. The exclusion regulations distinguish fully excluded products from products excluded only from specified provisions, and the outcome depends on the authorized product and its characteristics. This guide does not assess a drug, natural health product or medical-device application. S09 S20

The Canada Revenue Agency (CRA) administers the excise framework, with the Canada Border Services Agency (CBSA) collecting applicable duty on relevant imports. Provincial and territorial authorities regulate additional retail, access and other requirements; local requirements must be checked for the intended operation. A CRA licence or excise stamp is not Health Canada health-product authorization or provincial retail permission. S07 S11 S14 S15 S16

Product and operational access requirements

Formulation and nicotine concentration

For products within their scope, the Nicotine Concentration in Vaping Products Regulations set a maximum of 20 mg/mL, determined using the specified ISO method and conversion. They also prohibit packaging or selling a product in packaging that states a concentration above that limit. Scope includes products intended for retail sale in Canada and products otherwise furnished at ordinary retail points of sale; products authorized for sale under the Food and Drugs Act are excluded by section 3. S03

The regulations came into force on 8 July 2021 and contained a separate, short retailer transition. That historic transition is not a current sell-through allowance. Nor is the residual 66 mg/mL provision in the packaging regulations an alternative retail limit: it is expressly subject to the nicotine-concentration regulations. S03 S04

TVPA sections 7.21 and 7.22 and Schedule 2 prohibit specified ingredients in the relevant vaping substances. The list includes amino acids, caffeine, colouring agents, essential fatty acids, glucuronolactone, probiotics, taurine, vitamins and mineral nutrients. Schedule 2 expressly excepts prescription vaping substances and substances manufactured or sold for export; health-product exclusions also require their own analysis. These exceptions do not authorize an ordinary domestic consumer formulation. S01 S09

Packaging, warnings and container design

The Vaping Products Labelling and Packaging Regulations (VPLPR) contain distinct TVPA and CCPSA parts. For the ordinary consumer products addressed here:

  • Nicotine-containing products require a nicotine-concentration statement and a prescribed health warning. Placement depends on the product, packaging layers and kit configuration; copying a bottle label onto a pod carton may not meet the rules. S04
  • The incorporated List of Health Warnings for Vaping Products supplies the product warning. It is not interchangeable with the separate advertising-warning list. S13 S38
  • Part 2 requires an ingredient list for every vaping substance within its scope, with detailed placement and language rules. Nicotine-free does not mean label-free. S04
  • Section 50 requires child-resistant containers for immediate containers that are devices or parts, and for other immediate containers holding a substance at 0.1 mg/mL nicotine or more, subject to the exception where exposure to the substance in a form other than aerosol is impossible during reasonably foreseeable use. Section 57 separately addresses toxicity information at that nicotine threshold and its own exceptions. Do not collapse these provisions into “all liquids need the same childproof label.” S04

Part 1 and Part 2 exclude vaping products subject to the Food and Drugs Act. The VPLPR also contains a specific Part 2 import-to-comply or export exception with an evidence obligation; this is not general permission to sell a non-compliant import. S04

Manufacturing, importing and reporting

For TVPA purposes, “manufacture” is broader than making liquid: it includes packaging, labelling, distributing and importing for sale in Canada. The Vaping Products Reporting Regulations (VPRR) then apply their own definitions and product scope, excluding a person who only packages, labels or distributes on behalf of a manufacturer. Allocate duties by actual role rather than by a commercial job title. S01 S06

The VPRR covers specified devices, parts, substances and assortments intended for retail sale, including certain empty hardware—not every loose accessory indiscriminately. Products or assortments authorized under the Food and Drugs Act are excluded as specified in section 2(3). S06

The principal reporting requirements are:

  • Sales: January–June reports are due by 31 July; July–December reports are due by 31 January of the following year. These are half-yearly reports, not quarterly filings. S06
  • Ingredients: the report for a previously unreported brand is due on or before the manufacturer first sells it. Changes to specified ingredient information must be notified on or before the first sale of product manufactured in accordance with the change. The ingredient-report exception for products manufactured solely for export must not be extended to every reporting duty. S06
  • Forms: use the prescribed, current forms and submission method. Health Canada’s regulatory overview identifies reporting by manufacturers and importers; filing is a compliance obligation, not a product approval. S02 S06

VPRR filings also do not replace CCPSA record-keeping and incident-reporting duties. Sections 13 and 14 address those separate obligations; businesses need their own safety-reporting workflow. S44

Excise licensing, stamps and destination

The excise definition is not identical to the TVPA definition. For this regime, a vaping product is a vaping substance outside a device or a device containing a vaping substance; cannabis and tobacco products are excluded. An empty device may fall within the TVPA while not being a vaping product under this excise definition. Nicotine-free vaping substances can still attract duty. S32 S30

CRA’s guidance requires a vaping product licence to manufacture vaping products or import packaged products for stamping in Canada, with its stated personal-use manufacturing exception. An importer that does not manufacture or stamp in Canada must become a vaping prescribed person to obtain stamps. These are different compliance routes, not a universal licence for every retailer. Duty-paid distribution and retail also require attention to stamp and possession rules and applicable exceptions. S07 S21 S28 S45

CRA’s March 2026 calculation notice states the federal liquid-duty rates as C$1.12 per 2 mL or fraction for the first 10 mL, then C$1.12 per 10 mL or fraction above 10 mL. Corresponding gram-based rates apply to solids. The calculation is based on the substance in each immediate container or device—not simply the combined volume printed on a multipack. The notice identifies the same rates for the additional duty applicable to specified vaping provinces. These are excise rates, not an all-in tax or landed-cost quotation. S30

The retrieved coordinated-duty regulations and CRA notice identify Alberta, Manitoba, New Brunswick, Nova Scotia, Ontario, Prince Edward Island, Quebec, Northwest Territories, Nunavut and Yukon as specified vaping jurisdictions. The statutory term “specified vaping province” includes the listed territories. Destination-specific stamps evidence the additional duty; CRA describes the peach-coloured Canada stamp for jurisdictions outside the coordinated system. This distinction does not establish that no separate provincial tax applies. S25 S30 S11

Nova Scotia’s 2026 dates must be separated. SOR/2026-41 was made and came into force on 26 February 2026. CRA identifies 1 April 2026 for the additional duty, with qualifying-stock transition rules through 30 June. From 1 July, ordinary duty-paid retail stock must bear the Nova Scotia stamp. These transitions have expired by this guide’s verification date; they are not ongoing permission to sell Canada-stamped stock there. The statutory transition is limited to defined qualifying products, not every product held in inventory. S26 S11

Key restrictions and provincial differences

Age controls and remote sales

The TVPA defines a young person as someone under 18. Section 8 prohibits furnishing a product to a young person in a public place or place to which the public has access, and section 9 prohibits sending or delivering to a young person. Section 9 sets out separate sender and delivery-person defences, including specified identification steps; a website checkbox is not a substitute for analyzing those requirements. Section 13 provides a specific prescription-product exception. S01

Federal age rules are not a single national checkout setting. Ontario prohibits sale or supply below 19 and requires identification where the customer appears under 25. Prince Edward Island’s legislation and June 2026 retailer guidance identify a 21 threshold. Québec’s official guidance identifies 18 and prohibits online retail sales of electronic cigarettes. The provincial examples do not exhaust destination or local requirements. S34 S14 S36 S16 S15

Health Canada’s retrieved 2026–2028 plan describes proposed online/distance-sale age-verification regulations and anticipated consultation. A regulatory plan is not an enacted instrument. Existing youth-access duties must be applied now; the proposed scheme must not be described as already in force. S08

Promotion, flavours and local retail conditions

The TVPA restricts misleading promotion, health-benefit claims and comparisons with tobacco, with the statutory Food and Drugs Act authorization exception and regulatory qualifications. Its flavour provisions distinguish prohibited ingredients from youth-appealing flavour indications and the specific Schedule 3 promotion restrictions. These are not interchangeable with a ban on every flavoured liquid. S01

The Vaping Products Promotion Regulations restrict advertising that young people can see or hear, with defined exceptions. They separately regulate point-of-sale display, packages, brand elements and signs, and advertising health warnings. Certain provisions defer to applicable provincial legislation; an adult-only setting does not erase all remaining federal or provincial rules. Advertising-warning language also depends on the advertising’s language and the regulations, rather than a blanket statement that every advertisement must always be bilingual. S05 S38

Health Canada’s retrieved plan still describes the federal flavour/sensory initiative associated with the 19 June 2021 Part I proposal, with Part II publication timing “to be determined.” This guide does not present that proposed tobacco/mint/menthol framework as enacted law. Nor does the proposal establish permission to sell those flavours in a province. S08 S17

Selected provincial checkpoints illustrate the separate analysis:

  • Québec: official guidance prohibits flavours or aromas other than tobacco while retaining unflavoured products. Regulation sections 6.5–6.7 address product/pack information and apply the Act’s flavour restriction to electronic cigarettes. Section 6.6 imposes manufacturer/distributor sale standards including no more than 20 mg/mL nicotine, 2 mL liquid volume or 30 mL for refill containers, and youth-attractive design restrictions. The Québec government identifies 31 October 2023 as the commencement of the new measures. Do not treat these provincial volume limits as nationwide federal limits. S35 S40 S46
  • Ontario: provincial guidance limits sales of flavoured vapour products outside specialty vape stores or licensed cannabis retail stores, except menthol, mint and tobacco flavours. Specialty status has registration and operating conditions; it is not a general exemption from federal law. The page’s historical reference to products above 20 mg/mL must not be read as overriding the later federal concentration rules. S14 S03
  • Prince Edward Island: official retailer guidance identifies tobacconist-shop restrictions, flavour-related prohibitions and age controls. The Act prohibits retail products containing a prescribed flavouring agent. The complete prescribed-agent and product-exception analysis is outside this introductory guide; do not infer a permitted flavour list from this short example. S16 S36

Further checks for operators

Before relying on this framework for a launch, document:

  1. The actual product: intended use and claims; nicotine content; ingredients; device/part classification; packaging, safety and testing evidence; any health-product authorization and the precise associated exclusions.
  2. The responsible parties: who manufactures, imports, labels, distributes and reports; who holds the relevant CRA status; where and when stamping occurs; which party pays and accounts for duty.
  3. Each destination and channel: current provincial/territorial age, retail status, flavour, volume, display, promotion and remote-sale restrictions; delivery verification; applicable municipal requirements and separate taxes.
  4. The live legal position: later amendments, commencement instruments, incorporated warning/form updates and any relevant court orders. This introductory guide does not assess individual court orders or establish that every challenge or appeal is resolved.
  5. The advertising itself: exact copy, audience controls, warnings, language, placement, gifts or other promotion, and interaction between federal and provincial rules.

This is regulatory research, not a legal opinion or a product-specific assurance of market access. Independent review and any necessary specialist verification remain separate from publication authorization.

Official sources

All S references above link directly to the official source. Local research captures are supporting handover material, not publicly hosted attachments.